Journal of Clinical Oncology

Further Optimizing Care of Patients With Operable Hormone Receptor–Sensitive Breast Cancer

A Alexandra Thomas (Duke Cancer Institute, Duke University, Durham, NC) E Erica L. Mayer A Angela DeMichele (University of Pennsylvania School of Medicine, Philadelphia) N Nadia Harbeck (Breast Center, Department of Obstetrics and Gynecology and Comprehensive Cancer Center Munich, Ludwig Maximilians University Munich University Hospital, Munich, Germany) G Giuseppe Curigliano M Michail Ignatiadis V Virginie Adam (Breast International Group, Brussels, Belgium) Y Yang Zhou T Thelma P. Brown (University of Alabama at Birmingham, Birmingham, AL) L Leslie Gilham (Breast Cancer Trials, Newcastle, NSW, Australia) B Boon H. Chua K Kevin Kalinsky (Winship Cancer Institute, Emory University, Atlanta) A Antonio C. Wolff (Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD) S Seamus O'Reilly (Cancer Trials Ireland and Cork University Hospital, Dublin, Ireland)

Abstract

Harmonized global collaborations are crucial to improving outcomes in hormone sensitive operable breast cancer.

View Original
APA MLA Chicago BibTeX RIS

Article Details

Volume / Issue Vol. 43, Issue 5
Published February 10, 2025
Pages 487-491
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins
ISSN: 0732-183X Health Sciences

Authors (14)

A

Alexandra Thomas

Duke Cancer Institute, Duke University, Durham, NC

E

Erica L. Mayer

A

Angela DeMichele

University of Pennsylvania School of Medicine, Philadelphia

N

Nadia Harbeck

Breast Center, Department of Obstetrics and Gynecology and Comprehensive Cancer Center Munich, Ludwig Maximilians University Munich University Hospital, Munich, Germany

G

Giuseppe Curigliano

M

Michail Ignatiadis

V

Virginie Adam

Breast International Group, Brussels, Belgium

Y

Yang Zhou

T

Thelma P. Brown

University of Alabama at Birmingham, Birmingham, AL

L

Leslie Gilham

Breast Cancer Trials, Newcastle, NSW, Australia

B

Boon H. Chua

K

Kevin Kalinsky

Winship Cancer Institute, Emory University, Atlanta

A

Antonio C. Wolff

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

S

Seamus O'Reilly

Cancer Trials Ireland and Cork University Hospital, Dublin, Ireland

Related Articles from this Journal

Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer

Ismaela Anna Vascotto, Filippo Antonica et al. Aug 2026 10.1200/jco-26-00658

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial

Samer A. Srour, Jad Chahoud et al. Aug 2026 10.1200/jco-26-00388

Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection

Risako Komata, Kenju Ando et al. Aug 2026 10.1200/jco-26-00140

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)

Ghayas C. Issa, Branko Cuglievan et al. Aug 2026 10.1200/jco-26-01743

Reply to: Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer

Irbaz Bin Riaz, R. Bryan Rumble et al. Aug 2026 10.1200/jco-26-01001